Emergent BioSolutions (EBS) Payables (2010 - 2026)

Emergent BioSolutions' Payables history runs 17 years deep, the most recent figure standing at $39.5 million for Q1 2026.

• On a quarterly basis, Payables fell 32.01% year-over-year to $39.5 million in Q1 2026; TTM through Mar 2026 was $39.5 million, a 32.01% decrease from a year earlier, with the FY2025 full-year figure at $55.6 million, down 8.7% from the prior year.
• Payables retreated to $39.5 million in Q1 2026 per EBS's latest filing, from $55.6 million in the prior quarter.
• Across five years, Payables topped out at $1.1 billion in Q1 2023 and bottomed at $39.5 million in Q1 2026.
• The 5-year median for Payables is $137.8 million (2022), against an average of $331.7 million.
• Across the five-year window, Payables soared 673.87% in 2023 and plunged 89.61% in 2025, its largest moves.
• Year by year, Payables stood at $1.1 billion in 2022, then slumped by 50.42% to $525.9 million in 2023, then tumbled by 88.42% to $60.9 million in 2024, then slipped by 8.7% to $55.6 million in 2025, then fell by 28.96% to $39.5 million in 2026.
• Per Business Quant, the three latest EBS Payables figures stand at $39.5 million (Q1 2026), $55.6 million (Q4 2025), and $57.4 million (Q3 2025).